Xeris Biopharma Holdings, Inc. (XERS) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Xeris Biopharma’s revenue went from $20M in fiscal 2020 to $292M in fiscal 2025, growth of about 70.2% a year.
Net income in fiscal 2025 was $554000, a net margin of 0.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $368M and net income -$6M.
The diluted share count rose 305% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $368M | $292M | $203M | $164M | $110M | $50M | $20M |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | $47M | $25M | -$34M | -$44M | -$82M | -$115M | -$84M |
| Net income | -$6M | $554000 | -$55M | -$62M | -$95M | -$123M | -$91M |
| EPS (diluted) | $-0.04 | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 |
| R&D | $38M | $31M | $26M | $22M | $21M | $25M | $21M |
| Revenue growth | — | +43.7% | +23.9% | +48.7% | +122.3% | +142.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $74M | $29M | -$37M | -$47M | -$103M | -$96M | -$81M |
| Capital spending | -$1M | — | — | — | — | -$1M | -$377000 |
| Free cash flow | $73M | — | — | — | — | -$97M | -$81M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | $31M | $22M | $18M | $11M | $12M | $11M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $111M | $72M | $72M | $122M | $102M | $134M |
| Debt | — | $258M | $271M | $229M | $198M | $88M | $87M |
| Equity | — | $14M | -$30M | -$7M | $45M | $95M | $34M |
| Total assets | — | $384M | $323M | $323M | $345M | $304M | $159M |
| Shares (diluted) | 190M | 173M | 147M | 138M | 136M | 79M | 43M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | 12.7% | 8.5% | -16.6% | -26.9% | -74.3% | -232.2% | -408.8% |
| Net margin | -1.8% | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| FCF margin | 19.7% | — | — | — | — | -194.8% | -396.1% |
| ROIC | — | 9.2% | -13.4% | -19.4% | -33.2% | -62.8% | -54.6% |
| ROE | — | 4.0% | 185.2% | 917.9% | -209.5% | -128.9% | -270.0% |
Frequently asked questions
What is Xeris Biopharma’s annual revenue?
$292M in fiscal 2025 and $368M over the twelve months to September 30, 2026.
How much profit does Xeris Biopharma make?
Net income was $554000 in fiscal 2025 (net margin 0.2%).
Is Xeris Biopharma’s revenue growing?
Yes: revenue rose 43.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.